COVID proved the therapeutic potential of RNA technology – making it more available is the next goal
Detailed methodology to deliver RNA vaccines to cells was also not easily available to the research community.
- Detailed methodology to deliver RNA vaccines to cells was also not easily available to the research community.
- For these reasons we have published a protocol detailing how to make and package RNA with commercially available reagents.
How RNA therapies work
- The concept behind RNA therapies is elegant and simple, in theory.
- There are two distinct components: the RNA payload and the fatty envelope, made of lipid nanoparticles, which safely delivers the payload to cells.
- Read more:
Messenger RNA: how it works in nature and in making vaccinesIt is hard to believe now, but even in the early 2000s RNA therapies were widely considered to be a pipe dream.
Delivering the message
- RNA is a negatively charged, unstable molecule and cannot maintain its structure in the body without some sort of protective casing.
- It was only in the 2010s that lipid nanoparticles were developed and identified as a potential mechanism for delivery.
- Then, before injection into the body, this assemblage is converted to a neutral pH, reducing potential toxicity in the body.
Time in the spotlight
- By the time the COVID pandemic arrived, the essential components to make a viable RNA vaccine had emerged.
- RNA vaccines were especially appealing as they can be rapidly synthesised in the lab using just the genetic code of the virus.
- The result has been that labs around the world are developing their own techniques from scratch, leading to a grossly inefficient system.
The democratisation of RNA technology
- It is a standardised technique researchers can use as a baseline for RNA therapies without the need for proprietary products.
- This will mean more people around the world will be able to bring RNA technology into the clinic, broadening its scope, impact and safety.
- We have only seen the tip of the iceberg in terms of the therapeutic potential of RNA technology.
This work was supported by funding from New Zealand Ministry of Business Innovation and Employment (RTVU1603 and Vac 19008), Research Trust of Victoria University of Wellington (project number 400662) and The Hugh Green Foundation.